Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $29.3 million.

  • Lyell Immunopharma's Accumulated Expenses rose 103.76% to $29.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 103.76%. This contributed to the annual value of $40.8 million for FY2024, which is 4513.97% up from last year.
  • Latest data reveals that Lyell Immunopharma reported Accumulated Expenses of $29.3 million as of Q3 2025, which was up 103.76% from $28.0 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Accumulated Expenses high stood at $40.8 million for Q4 2024, and its period low was $21.4 million during Q2 2022.
  • In the last 5 years, Lyell Immunopharma's Accumulated Expenses had a median value of $26.8 million in 2024 and averaged $27.2 million.
  • In the last 5 years, Lyell Immunopharma's Accumulated Expenses tumbled by 1631.73% in 2022 and then skyrocketed by 4513.97% in 2024.
  • Over the past 5 years, Lyell Immunopharma's Accumulated Expenses (Quarter) stood at $29.1 million in 2021, then dropped by 1.04% to $28.8 million in 2022, then decreased by 2.19% to $28.1 million in 2023, then surged by 45.14% to $40.8 million in 2024, then fell by 28.2% to $29.3 million in 2025.
  • Its Accumulated Expenses stands at $29.3 million for Q3 2025, versus $28.0 million for Q2 2025 and $31.2 million for Q1 2025.